Industry Workshops

Industry Workshops provide an opportunity for AMCP corporate members to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.

All Industry Workshops take place on Wednesday, Oct. 12, from 11:30am–12:30pm.

Clinical Overview of Duchenne Muscular Dystrophy and an Update on an Investigational Gene Transfer Therapy 

Sponsored by Sarepta 

Room: National Harbor 3 

Description: Duchenne muscular dystrophy (DMD) is a rare, genetic, neuromuscular disease characterized by progressive muscle weakness resulting from the absence of dystrophin protein in skeletal and cardiac muscle cells. This session will provide a comprehensive overview of the complexities of Duchenne as a disease state and the current treatment landscape before diving deeper into gene transfer therapy research, including a summary of the current clinical development program for investigational delandistrogene moxeparvovec.


  • Duchenne Muscular Dystrophy: Diagnosis and Assessment of Disease Progression 
    • Faculty: 
  • Gene Transfer Therapy: Overview of Investigational AAV-Based Gene Transfer Therapy and Study Design Considerations 
    • Faculty:
      Kathrin Kucharski, PharmD, BCPS 
      Sarepta Therapeutics 
  • Investigational Delandistrogene Moxeparvovec: A Clinical Development Program Summary
    • Faculty:
      Kathrin Kucharski, PharmD, BCPS 
      Sarepta Therapeutics 
Next Generation Add-On Treatment of Inattention in ADHD: A Discussion Regarding a New Prescription Digital Therapeutic

Sponsored by Akili

Room: National Harbor 2

Description: The ongoing cognitive health crisis continues to be a clinical and economic burden in the United States. Millions of people do not receive adequate treatment for cognitive impairment. For example, research has shown that the inattention and focusing difficulty seen in people with ADHD contribute to its classification as a cognitive impairment, but a general lack of awareness of these issues leads some to see ADHD as purely behavioral. This misappropriation has a negative effect on over 16 million people who have been diagnosed with ADHD in the United States, including over 6 million children. Although traditional ADHD management combines medications and psychosocial services, in many cases these treatments alone do not sufficiently manage ADHD symptoms. There is a need for a novel approach to treating ADHD that can complement a multimodal treatment plan.

Everyone deserves to have access to new and innovative treatments that address gaps in the current treatment landscape. But where do PDTx fit within the ADHD treatment protocol? How do they elevate the standard of care in ADHD? This session will highlight the role of PDTx in the management of ADHD with a focus on gaps in the current standard of care and strategies to navigate the access landscape for PDTx.

Learning Objectives

  • Understand the cognitive health crisis that exists today and the promise of PDTx to provide a solution
  • Discuss ADHD and the gaps within the current standard of care
  • Discuss the place in therapy and treatment protocol of current PDTx to treat ADHD
  • Understand strategies to help overcome the challenges of PDTx coverage, including formulary decision making, coding, billing, and reimbursement
RNA Interference (RNAi): Harnessing the Potential of Gene Silencing To Create Transformative Medicines

Sponsored by Alnylam

Room: National Harbor 11

Description: Alnylam provides an overview of the evolution of RNA interference, its uses in medicine today and the exciting potential of future applications.

Sami Nasrawi
Director, Medical Outcomes Science Liaison

Understanding Chronic Cough: Patient Presentation and Assessment

Sponsored by Merck

Room: National Harbor 10

Learning Objectives:

  1. Discuss patient cases and understand patient presentation of chronic cough.
  2. Review clinical guidelines.
  3. Understand potential mechanisms of disease in chronic cough.

Sidney S. Braman, MD

Industry Workshop sponsorship opportunities are available for AMCP Corporate Members in good standing. Contact Beth O’Brien, director of meetings and conventions, at for more details.